A Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
This is a phase 1, 2-part, global, multicenter, open-label, PK, safety and tolerability study
of oral tazemetostat in subjects with either advanced solid tumors, or hematological
malignancies and normal hepatic function or moderate, or severe hepatic impairment.